Newsletter Signup | Join Community
Skin cancer is the most common cancer in the United States. What you need to know about Melanoma & its Treatment.
A history of melanoma, certain cancer treatments and other cancers may all increase the risk of developing melanoma.
Early detection of skin melanoma is best accomplished by a Dermatolgist and this may translate into improved survival.
Stage II Melanoma is treated with surgery and some individuals may benefit from adjuvant therapy.
Yervoy + Opdivo Improves Overall Survival in Advanced Melanoma; Average Survival May Exceed 4 Years
Keynote 054 clinical trial establishes Keytruda as standard treatment for stage III melanoma and leads to FDA approval.
Stay Current With Melanoma Treatment Advances & Connect with Others
Research suggests that adjuvant radiation may reduce melanoma recurrences in stage III patients at risk of local relapse
Cancer Connect - Treatment of In Situ & Stage 1 Melanoma
Biomarkers drive new drug development in melanoma
University of Texas MD Anderson Cancer Center begins trials with WP1066 for melanoma metastatic brain
Treatment of Stage IV Melanoma Cancer
Understand the administration, side effects and answers to frequently asked questions about Braftovi™ (Enorafenib)
Nature study suggests checkpoint inhibitors can be used to treat Desmoplastic Melanoma
Cancer Connect - Treatment of Recurrent Melanoma
Anti-LAG-3 in Combination with Opdivo Show Activity in Patients with Melanoma Who Failed Anti-PD-1/PD-L1 Therapy.
First ever FDA-approved oncolytic virus therapy, has been approved for the treatment of melanoma.
New Combination Treatment Effective Against Melanoma Skin Metastases.
Moffitt Researchers Discover Mechanism Leading to Drug Resistance, Metastasis in Melanoma Patients.
Final Budget Bill Doubles DoD Funding Available for Melanoma Research.
PV-10 Injection Promising Treatment of Melanoma Lesions.
Memorial Sloan Kettering Team Makes Key Discovery in Understanding Immunotherapy’s Successes—And Its Failures.
Study of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow Crossover.
Viagra Associated with Increased Risk of Melanoma.
Melanoma Patients with Atypical Moles at High Risk of Additional Melanoma
Selumetinib Active Against Melanoma of the Eye
Company Will Seek FDA Approval of a New Vaccine to Treat Melanoma
Aspirin Reduces Risk of Melanoma in Women
Women More Likely to Survive Melanoma Than Men
Chemotherapy to Liver Delays Progression of Metastatic Melanoma
Sunscreen Use More Common Among Certain Latinos
Vitamin D and Calcium May Reduce Melanoma Risk in High-Risk Women
Sylatron Approved for Melanoma
Advanced Melanoma Patients May Benefit from PV-10
How Much Follow-up Is Appropriate for Melanoma Survivors?
Delcath PHP System Effective Against Liver Metastases
Melanoma More Deadly in Young White Men than Women
Hispanics and African Americans Present with More Advanced Melanoma than Whites
Nexavar® Fails to Improve Melanoma Survival
Gleevec® May Be Effective for Some Patients with Metastatic Melanoma
Nexavar® Shows Promise for the Treatment of Advanced Melanoma
Patient’s Own Immune Cells Help Attack Melanoma
Paraplatin®, Taxol®, and Avastin® Beneficial for Metastatic Melanoma
Careful Follow-Up Screening Improves Outcomes for Melanoma Patients
Experimental Vaccine Improves Melanoma Outcomes
What is the role of interferon in the management of melanoma?
Surveillance Guidelines for Stage I-III Malignant Melanoma Published by American Joint Committee on Cancer
Less Extensive Surgical Technique may Reduce Scarring from Melanoma Surgery
Autologous Hapten-Modified Melanoma Vaccine Appears to Affect Survival after Resection of Lymph Node Metastasis
Combination of Paclitaxel and Tamoxifen Shows Activity Against Metastatic Melanoma
Herpes Injection May Help Achieve Anti-Cancer Responses in Melanoma Treatment
A 15-Year Follow-Up of Patients Receiving a Vaccine as Adjuvant Therapy of Melanoma Shows Expanded T-Cell Populations
Five-Year Follow-Up Suggests that Vaccine is Effective in Preventing Recurrence of Melanoma Following Surgical Resection
Oncophage® Produces Immune Responses in Metastatic Melanoma
Oncophage® Improves Survival in Metastatic Melanoma
Arginine Deprivation Slows Metastatic Melanoma
Vinorelbine Plus Tamoxifen Produces Prolonged Responses in Persons with Metastatic Malignant Melanoma
Abraxane™ Evaluated for Treatment of Metastatic Melanoma
Vaccine May Prolong Time to Progression and Survival in Patients with Stage III Melanoma
Addition of Genasense® to Dacarbazine Improves Outcomes in Subset of Metastatic Melanoma Patients
Interleukin-2 and Dacarbazine Combo Produces Responses in Metastatic Melanoma that Has Spread to the Lung
Thin Melanomas Responsible for Many Melanoma Related Deaths.
Vaccine to Stimulate Immune System Appears Promising for Advanced Melanoma
Skin Test May Help Determine Effectiveness of Vaccine Treatment for Melanoma Patients
No Benefit for Stage II Melanoma with Addition of Isotretinoin
Low Levels of HLA-DR Predict for Worse Prognosis in Early Melanoma
Paclitaxel plus Carboplatin Benefits Some Patients with Metastatic Melanoma
Novel Immune Approach Helps Fight Metastatic Melanoma
Ipilimumab Improves Outcomes in Advanced Melanoma
Vaccine May Improve Survival in Patients with Advanced Melanoma
Appearance of Congenital Nevi Improved with Laser Resurfacing
Immunotherapy may Benefit some Advanced Melanoma
Radiation Therapy Helps Prevent Local Recurrences in Melanoma
Vaccine may Improve Survival in Metastatic Melanoma
Biologic Therapy, GM-CSF, May Be Effective Treatment after Surgery for Metastatic Melanoma
Immune Stimulating Vaccine Promising in Metastatic Melanoma
An investigation BRAF inhibitor, GSK2118436, appears active in melanoma patients with brain metastases.
Expanded Access Program Initiated for Genasense®/Dacarbazine for Patients with Advanced Melanoma
Melanoma Research Alliance
Novel Treatment Strategies Needed for Advanced Melanoma
Changes in Moles Add to Criteria of Early Detection of Melanoma
Targeted Therapy with Volociximab and DTIC Well Tolerated in Metastatic Melanoma
Vaccine Promising in Metastatic Melanoma
Engineered Immune Cells May Help Fight Melanoma
Aggressive combination chemotherapy found to be no better than single-agent chemotherapy for metastatic melanoma.
Therapy Involving Patient’s Immune Cells Effective for Refractory, Advanced Melanoma
Histamine Plus Interleukin-2 Produces Responses in Advanced Melanoma
Melanoma Rates Increase in Children
Melanoma More Likely to Be Diagnosed at Advanced Stage in Non-White Patients
Parkinson’s Treatment Unlikely to Be Linked with Melanoma
Temozolomide Is More Effective than Intravenous Dacarbazine against Metastatic Malignant Melanoma
Genasense® Improves Survival in Some Patients with Advanced Melanoma
Noninvasive Technique Identifies Melanoma
Desmoplastic Melanoma Less Likely to Recur than Thought
High-Dose Interleukin-II May Not Improve Outcomes of Patients with Metastatic Melanoma
Marathon Runners at Increased Risk of Melanoma
Controlling CNS Progression in Patients with Metastatic Melanoma
Patients with Endometriosis at Increased Risk for Melanoma
Vaccination with Irradiated Autologous Tumor Cells May Improve Outcomes for Patients with Regional Lymph Node
New Vaccine for Malignant Melanoma: Preliminary Results Show TriGem Vaccine May Help Prevent Disease Progression
Radiofrequency Ablation Effective for Primary Lung Tumors and Lung Metastases from Melanoma
Mobile Phone Use Not Linked with Melanoma of the Eye
Lymphoma that Manifests in the Testicle: New Therapies, such as Additional Surgery, Radiation Therapy, or Chemotherapy
FDA Grants Orphan Drug Status to Oncophage® Vaccine for Metastatic Melanoma
Anyone have experience with TVEC? Looking to learn from others. Thanks
A new very active treatment option for Melaoma-Braftovihttps://mavendoctors…